Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Oncology·MeSH: Lymphoma, Large B-Cell, Diffuse
Prevalence
56.0 / 100K
Incidence
19.6 / 100K/yr
2 drugs in development·1 company·3 clinical trials
Drug Pipeline by Phase
Compare drugs
Frequently asked questions
How many drugs are in development for Diffuse Large B-Cell Lymphoma, Not Otherwise Specified?
BioSniper tracks 2 drugs in development for Diffuse Large B-Cell Lymphoma, Not Otherwise Specified across 1 company.
How many clinical trials target Diffuse Large B-Cell Lymphoma, Not Otherwise Specified?
There are 3 clinical trials targeting Diffuse Large B-Cell Lymphoma, Not Otherwise Specified tracked by BioSniper.
What is the prevalence of Diffuse Large B-Cell Lymphoma, Not Otherwise Specified?
The estimated prevalence of Diffuse Large B-Cell Lymphoma, Not Otherwise Specified is approximately 56.0 per 100,000 population.
Deep-dive into Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis